Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-Week Symptomatic Effect Evaluation to Compare Celecoxib 200 mg QD, Celecoxib 200 mg BID and Diclofenac 75 mg SR BID in Patients With Ankylosing Spondylitis

NCT00648141 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00648141
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00648141 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-Week Symptomatic Effect Evaluation to Compare Celecoxib 200 mg QD, Celecoxib 200 mg BID and Diclofenac 75 mg SR BID in Patients With Ankylosing Spondylitis
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2003
Completion date
January 31, 2005
Enrollment
458 (actual)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

spondylitis, ankylosing